Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients

Real-life data that support effectiveness of secukinumab (SEC), an interleukin 17A inhibitor, in Poland are few. We aimed to evaluate SEC effectiveness based on drug retention and safety measures reported in electronic medical records (EMRs) of patients with psoriatic arthritis (PsA) and ankylosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Moskal, Mateusz, Krawiec, Piotr, Zaręba, Wojciech, Świerczek, Izabella, Ratusznik, Jakub, Raputa, Wiktor, Zieliński, Maciej, Batko, Krzysztof, Huk, Mikita, Batko, Bogdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737777/
https://www.ncbi.nlm.nih.gov/pubmed/36497938
http://dx.doi.org/10.3390/ijerph192315861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737777/
https://www.ncbi.nlm.nih.gov/pubmed/36497938
http://dx.doi.org/10.3390/ijerph192315861

Ejemplares similares